ExodusPoint Capital Management’s Solid Biosciences SLDB Stock Holding History

ExodusPoint Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-62,801	Closed	-$438K	–	2000
2024 Q3	$438K	Buy	62,801 +27,971	+80%	+$227K	﹤0.01%	1239
2024 Q2	$197K	Buy	34,830 +10,745	+45%	+$96.2K	﹤0.01%	1398
2024 Q1	$321K	Buy	+24,085	New	+$225K	﹤0.01%	1247
2022 Q1	–	Sell	-4,272	Closed	-$112K	–	2634
2021 Q4	$112K	Buy	4,272 +2,673	+167%	+$81.7K	﹤0.01%	1941
2021 Q3	$57K	Sell	1,599 -547	-25%	-$23.2K	﹤0.01%	1964
2021 Q2	$118K	Buy	2,146 +592	+38%	+$39.1K	﹤0.01%	2116
2021 Q1	$129K	Sell	1,554 -1,505	-49%	-$167K	﹤0.01%	1947
2020 Q4	$348K	Buy	+3,059	New	+$193K	﹤0.01%	1460

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ExodusPoint Capital Management's SLDB Position: Q4 2024 in Review

ExodusPoint Capital Management sold out of Solid Biosciences (SLDB) in Q4 2024, closing a stake of 62,801 shares — an estimated $438K sold.

ExodusPoint Capital Management first reported a position in SLDB in Q4 2020 and held it in 8 quarters. The position peaked at $438K in Q3 2024. 90 funds tracked by Wall St. Rank hold SLDB as of Q4 2024.

ExodusPoint Capital Management reported no remaining Solid Biosciences position as of Q4 2024 after selling out during the quarter.
ExodusPoint Capital Management sold 62,801 Solid Biosciences shares in Q4 2024, an estimated $438K.
ExodusPoint Capital Management first reported a position in Solid Biosciences in Q4 2020 and held it in 8 quarters.
ExodusPoint Capital Management's Solid Biosciences position peaked at $438K in Q3 2024.
90 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.